Annotation Detail

Information
Associated Genes
MET
Associated Variants
MET EXON 14 SKIPPING MUTATION
MET EXON 14 SKIPPING MUTATION
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
Pts with MET exon 14-altered NSCLC were enrolled into an expansion cohort of the phase I PROFILE 1001 study (NCT00585195) and received crizotinib. Responses were assessed. By data-cut off 18 pts with MET exon 14-altered NSCLC had enrolled and 17 received treatment (15 response-evaluable). Antitumor activity per RECIST was documented in 10/15 pts: 5 with confirmed PRs and 5 with unconfirmed PRs. Median PFS could not be calculated, with no deaths or PD by the data cut-off. Treatment-related AEs were generally tolerable, and were most commonly edema, nausea, vision disorder, bradycardia, and vomiting. AEs were mostly grade 1 or 2, with one grade 3 edema, and no grade 4/5 AEs.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7642
Gene URL
https://civic.genome.wustl.edu/links/genes/52
Variant URL
https://civic.genome.wustl.edu/links/variants/324
Rating
1
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Crizotinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Drugs
Drug NameSensitivitySupported
CrizotinibSensitivitytrue